Survival Outcomes of Sequential Therapies in Malignant Pleural Mesothelioma: A Real-World Analysis of Second-Line Treatment With Nivolumab or Carboplatin-Pemetrexed
JCO Oncology Practice · 20.11.2026
DOI: 10.1200/op-26-00765 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 20.11.2026. Verfasst von Michele Maffezzoli und 16 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Purpose
Optimal treatment sequencing in malignant pleural mesothelioma (MPM) remains uncertain, particularly after progression on first-line (1L) treatment. We assessed real-world outcomes of patients receiving second-line (2L) carboplatin-pemetrexed (CARBO-PEM) after nivolumab-ipilimumab (NIVO-IPI), or 2L nivolumab (NIVO) after CARBO-PEM and explored the prognostic value of the Mesothelioma Risk Score (MRS) in the 1L setting. Materials and Methods This multicenter retrospective study included patients with advanced MPM treated across five UK institutions between May 2015 and November 2025. Eligible patients received either 2L CARBO-PEM after NIVO-IPI, or 1L CARBO-PEM followed by 2L NIVO. The primary end point was overall survival (OS) from 1L treatment initiation.
Results
Overall, 147 patients were included, and 54 received NIVO-IPI followed by CARBO-PEM and 93 received CARBO-PEM followed by NIVO. The median age was 73.8 years and 83.0% had epithelioid histology. The median follow-up was 43.3 months from 1L initiation. The median OS was 23.55 months with CARBO-PEM followed by NIVO versus 25.53 months with NIVO-IPI followed by CARBO-PEM (hazard ratio 1.28 [95% CI, 0.82 to 2.01]; P = .270). The median PFS 2L was 3.65 months with 2L NIVO versus 6.15 months with 2L CARBO-PEM, without statistical significance, while median OS 2L was 12.53 months and 14.11, respectively. In the 1L setting, MRS showed limited discrimination for PFS and OS. Grade ≥2 irAEs during NIVO-IPI were associated with longer PFS 1L but not OS.
Conclusion
In patients with MPM receiving 2L therapy, CARBO-PEM after NIVO-IPI remains clinically active, and OS appeared similar across treatment sequences. These findings support sequence flexibility in fit patients but highlight the need for more robust prognostic biomarkers.
Zitieren
APA
Maffezzoli, M., Lau, J., Dungey, M., Postaleniec, E., Neola, G., Formisano, L., Yusof, H. M., Acharige, S. M., Kim, M. R., Cave, J., Elgendy, M., Zarroug, M., Mangan, Y., Zaki, K., Dulloo, S., Fennell, D. A., & Banna, G. L. (2026). Survival Outcomes of Sequential Therapies in Malignant Pleural Mesothelioma: A Real-World Analysis of Second-Line Treatment With Nivolumab or Carboplatin-Pemetrexed. JCO Oncology Practice. https://doi.org/10.1200/op-26-00765
Vancouver
Maffezzoli M, Lau J, Dungey M, Postaleniec E, Neola G, Formisano L, et al. Survival Outcomes of Sequential Therapies in Malignant Pleural Mesothelioma: A Real-World Analysis of Second-Line Treatment With Nivolumab or Carboplatin-Pemetrexed. JCO Oncology Practice. 2026. doi:10.1200/op-26-00765
BibTeX
@article{Maffezzoli2026,
author = {Maffezzoli, Michele and Lau, Jason and Dungey, Maurice and Postaleniec, Emilia and Neola, Giuseppe and Formisano, Luigi and Yusof, Harliana Mohd and Acharige, Shyamika Mirisse and Kim, Mi Rim and Cave, Judith and Elgendy, Manal and Zarroug, Maha and Mangan, Yvonne and Zaki, Kam and Dulloo, Sean and Fennell, Dean A. and Banna, Giuseppe Luigi},
title = {Survival Outcomes of Sequential Therapies in Malignant Pleural Mesothelioma: A Real-World Analysis of Second-Line Treatment With Nivolumab or Carboplatin-Pemetrexed},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-26-00765}
}
EUVIMED